The primary objective of this trial was to evaluate the efficacy and safety of two maintenance doses of immunologically enhanced , standardised quality ( SQ + ) grass subcutaneous immunotherapy ( SCIT ) -LSB- @,@ SQ + and @,@ SQ + ; AVANZ ( ) Phleum pratense ( ALK ) -RSB- compared with placebo .